Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(50%)

Phase Distribution

Ph not_applicable
1
50%
Ph phase_4
1
50%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 4Post-market surveillance
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Terminated(1)

Detailed Status

Terminated1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
0.0%
Most Advanced
Phase 4

Trials by Phase

Phase 41 (50.0%)
N/A1 (50.0%)

Trials by Status

terminated150%
enrolling_by_invitation150%

Recent Activity

0 active trials
Showing 2 of 2
enrolling_by_invitationnot_applicable

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

NCT07568574
terminatedphase_4

The Menopause Transition: Estrogen Variability, Stress Reactivity and Mood

NCT03003949

Clinical Trials (2)

Showing 2 of 2 trials
NCT07568574Not Applicable

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

Enrolling By Invitation
NCT03003949Phase 4

The Menopause Transition: Estrogen Variability, Stress Reactivity and Mood

Terminated

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2